MARKET

IMRX

IMRX

Immuneering Corp
NASDAQ
4.160
-0.110
-2.58%
After Hours: 4.160 0 0.00% 19:30 09/28 EDT
OPEN
4.250
PREV CLOSE
4.270
HIGH
4.250
LOW
4.125
VOLUME
598.65K
TURNOVER
--
52 WEEK HIGH
8.48
52 WEEK LOW
3.860
MARKET CAP
269.14M
P/E (TTM)
-4.0349
1D
5D
1M
3M
1Y
5Y
1D
Immuneering presents new data at 2026 AACR on atebimetinib
TipRanks · 22h ago
Atebimetinib’s Weight-Preservation and Survival Benefits in Pancreatic Cancer Underscore Buy Rating and Unchanged $14 Price Target
TipRanks · 23h ago
Weekly Report: what happened at IMRX last week (0921-0925)?
Weekly Report · 1d ago
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Barchart · 1d ago
Immuneering to Present at the ESMO Congress 2026
Barchart · 5d ago
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH), TriSalus Life Sciences (TLSI) and Immuneering (IMRX)
TipRanks · 09/22 09:40
Weekly Report: what happened at IMRX last week (0914-0918)?
Weekly Report · 09/21 09:22
Weekly Report: what happened at IMRX last week (0907-0911)?
Weekly Report · 09/14 09:23
More
About IMRX
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.

Webull offers Immuneering Corp stock information, including NASDAQ: IMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMRX stock methods without spending real money on the virtual paper trading platform.